Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017121 | 0.84 | HTR1D (0.37) | TAAR1 | |
| SCHEMBL4023686 | 0.84 | HTR3A (0.37) | SLC6A4TAAR1 | |
| SCHEMBL4436017 | 0.84 | TAAR1 (0.44) | TAAR1MAOB | |
| SCHEMBL4016068 | 0.82 | MAPK1 (0.43) | SLC6A4SLC6A3TAAR1MAOB | |
| SCHEMBL4021112 | 0.80 | HTR2A (0.41) | KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4023123 | 0.76 | TAAR1 (0.40) | SLC6A2SLC6A4SLC6A3TAAR1MAOB | |
| SCHEMBL5449844 | 0.75 | TACR1 (0.42) | — | |
| SCHEMBL9111411 | 0.74 | CYP19A1 (0.43) | TAAR1 | |
| SCHEMBL9093168 | 0.72 | HRH3 (0.49) | MAOB | |
| SCHEMBL5558447 | 0.71 | LTA4H (0.41) | TAAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227469-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-08-06 | — | — | US | disclosed |
| US-7534798-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | KCNH2 371/4885SLC6A2 910/4885SLC6A4 691/4885 |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KCNH2 371/4885SLC6A2 910/4885SLC6A4 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.